Literature DB >> 11720483

Establishment of two new human bladder carcinoma cell lines, CAL 29 and CAL 185. Comparative study of cell scattering and epithelial to mesenchyme transition induced by growth factors.

N Cattan1, N Rochet, C Mazeau, E Zanghellini, B Mari, C Chauzy, H Stora de Novion, J Amiel, J L Lagrange, B Rossi, J Gioanni.   

Abstract

We describe here two new human urothelial carcinoma cell lines, CAL 29 and CAL 185, established from two patients with high-grade tumours and which display very different properties in vitro. We have shown that CAL 29 cells were tumorigenic in mice and expressed characteristic features of both cell scattering and transition from epithelial to mesenchymal phenotype (EMT) after triggering by the EGF receptor ligands, TGFalpha and EGF. At the opposite, the CAL 185 cells were not tumorigenic in mice and neither scattered nor expressed vimentin intermediary filaments in the presence of growth factors. We further demonstrated that CAL 29 cell scattering was reversible after growth factor removal and that both scattering and EMT were markedly impaired after treatment with MEK, Src and PI3-kinase inhibitors suggesting that these kinases might be important components of the cellular responses to EGF and TGF-alpha leading to scattering and EMT. These agents could help to understand the intracellular pathways involved in invasiveness and to find new targets for limiting metastasis. In conclusion, these two new cell lines could be good models to dissect the molecular mechanisms involved in invasion and metastasis development in human bladder cancer. Copyright 2001 Cancer Research Campaign

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720483      PMCID: PMC2375255          DOI: 10.1054/bjoc.2001.2105

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Characterization of the signaling pathways regulating alpha2beta1 integrin-mediated events by a pharmacological approach.

Authors:  V Petit; B Boyer; J P Thiery; A M Vallés
Journal:  Cell Adhes Commun       Date:  1999

2.  The impact of iatrogenic urothelial trauma on urinary levels of transforming growth factor-alpha.

Authors:  C S Cooper; W A See
Journal:  J Urol       Date:  1992-06       Impact factor: 7.450

Review 3.  Epithelial cell plasticity in development and tumor progression.

Authors:  J P Thiery; D Chopin
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

4.  [A new technic of analysis of the human karyotype].

Authors:  B Dutrillaux; J Lejeune
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1971-05-17

5.  Reversible transition towards a fibroblastic phenotype in a rat carcinoma cell line.

Authors:  B Boyer; G C Tucker; A M Vallés; J Gavrilovic; J P Thiery
Journal:  Int J Cancer Suppl       Date:  1989

6.  Expression of transfected transforming growth factor alpha induces a motile fibroblast-like phenotype with extracellular matrix-degrading potential in a rat bladder carcinoma cell line.

Authors:  J Gavrilović; G Moens; J P Thiery; J Jouanneau
Journal:  Cell Regul       Date:  1990-12

7.  Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells.

Authors:  P Savagner; A M Vallés; J Jouanneau; K M Yamada; J P Thiery
Journal:  Mol Biol Cell       Date:  1994-08       Impact factor: 4.138

8.  Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells.

Authors:  B Boyer; G C Tucker; A M Vallés; W W Franke; J P Thiery
Journal:  J Cell Biol       Date:  1989-10       Impact factor: 10.539

9.  Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer.

Authors:  V Ravery; M Colombel; Z Popov; S Bastuji; J J Patard; J Bellot; C C Abbou; Y Fradet; D K Chopin
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

10.  Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder.

Authors:  T Imai; M Kimura; M Takeda; Y Tomita
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more
  6 in total

1.  Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells.

Authors:  Julia Schulte; Michaela Weidig; Philipp Balzer; Petra Richter; Marcus Franz; Kerstin Junker; Mieczyslaw Gajda; Karlheinz Friedrich; Heiko Wunderlich; Arne Östman; Iver Petersen; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2012-07-22       Impact factor: 4.304

2.  Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.

Authors:  Banu Iskender; Kenan Izgi; Esra Hizar; Johann Jauch; Aslihan Arslanhan; Esra Hilal Yuksek; Halit Canatan
Journal:  Tumour Biol       Date:  2015-12-30

3.  Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer.

Authors:  Astrid Enkelmann; Joana Heinzelmann; Ferdinand von Eggeling; Martina Walter; Alexander Berndt; Heiko Wunderlich; Kerstin Junker
Journal:  J Cancer Res Clin Oncol       Date:  2010-07-04       Impact factor: 4.553

Review 4.  Current status of SRC inhibitors in solid tumor malignancies.

Authors:  Lauren N Puls; Matthew Eadens; Wells Messersmith
Journal:  Oncologist       Date:  2011-04-26

5.  ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.

Authors:  Erica di Martino; Olivia Alder; Carolyn D Hurst; Margaret A Knowles
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

6.  Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.

Authors:  Martin Kerr; Helen E Scott; Blaz Groselj; Michael R L Stratford; Katalin Karaszi; Naomi L Sharma; Anne E Kiltie
Journal:  Clin Cancer Res       Date:  2014-09-15       Impact factor: 12.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.